Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00386061 · ClinicalTrials.gov registry record · Phase 3
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,507
- Enrollment target
NCT00386061 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 1,507 participants.
The verdict
NCT00386061, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,507 participants
- Enrollment target
Study Summary
The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities. The main secondary objectives were to assess the effect of SR141716 on lipid parameters (HDL-C, TG), glucose tolerance status, the rate of patients with metabolic syndrome, waist circumference, glycemic parameters.
Interventions
- DRUG rimonabant (SR141716)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,507 participants |
| Start Date | 2001-10 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00386061
The ClinicalTrials.gov registry entry for NCT00386061 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,507 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rimonabant (SR141716) is the first listed.
NCT00386061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00386061 about?
NCT00386061 is a clinical study titled "Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)". The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities. The main secondary objectives were to assess the effect of SR141716 on lipid parameters...
What is the current status of trial NCT00386061?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,507 participants. The study started on 2001-10. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00386061?
The interventions under investigation include: rimonabant (SR141716) (DRUG).
Who is sponsoring clinical trial NCT00386061?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.